The Bern Heart and Brain Interaction Study - Interaction Between Brain and Heart in Acute Ischemic Stroke
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Oct 23, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Bern Heart and Brain Interaction Study is researching how the heart and brain interact during an acute ischemic stroke, which happens when blood flow to the brain is blocked. Understanding the different reasons for this blockage is important because it can help doctors provide better care and reduce the chances of a stroke happening again. The study is currently looking for participants aged 18 to 85 who have experienced a stroke within the last 12 hours and have undergone an MRI that shows signs of this condition.
If you or a family member are considering joining this trial, you will need to provide informed consent, which means you agree to participate after being fully informed about the study. However, pregnant individuals and those with certain medical conditions, like severe kidney failure or specific issues with MRI scans, cannot participate. If eligible, participants can expect to undergo tests and evaluations that will help researchers learn more about the relationship between heart health and stroke recovery. Your involvement could contribute valuable information to improve future treatments for stroke patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent as documented by signature.
- • Age: ≥ 18 and \< 86 years.
- • Acute ischemic stroke with symptom onset within 12 hours before admission to hospital.
- • Diagnosis of acute ischemic stroke with MRI with diffusion restriction as seen on diffusion weighted imaging.
- Exclusion Criteria:
- • Pregnancy. A negative pregnancy test upon admission is required for all women with child-bearing potential.
- • Standard contraindication for performing MRI.
- • Severe renal failure (GFR \<40).
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, Be, Switzerland
Patients applied
Trial Officials
Simon Jung, PD Dr. med.
Study Director
Dep. of Neurology, Inselspital Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials